North American bladder cancer market is estimated to grow significantly at a CAGR of around 9.6% during the forecast period. Major factors that are augmenting the growth of the North American bladder cancer market include increasing healthcare expenditure, raising awareness of cancer among the population, and surging aging population base coupled with the significant prevalence of bladder cancer across the region. Moreover, the presence of key market players in the region is also augmenting the market growth. Major players that are significantly present in the region are Pfizer, Inc., and Spectrum Pharmaceuticals, Inc.
A full report of North American Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/north-american-bladder-cancer-market
North American bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. Transitional cell bladder cancer is the most common type of bladder cancer. As per the Canadian Cancer Society, it makes up over 90% of all bladder cancers.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-bladder-cancer-market
The companies which are contributing to the growth of the North American bladder cancer market include AstraZeneca PLC, Astellas Pharma Inc., Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc., and Spectrum Pharmaceuticals, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in December 2019, Astellas Pharma Inc. announced that the FDA granted accelerated approval to PADCEV for treating adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting.
North American Bladder Cancer Market- Segmentation
By Cancer Type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Others (Sarcomas, Carcinoma in Situ)
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
